NICE has led the way in approving the breakthrough treatment for Multiple Myeloma, which is a long-term, incurable cancer of the blood plasma cells that goes through periods where symptoms worsen (relapse) and periods where treatment brings the disease under control (remission). Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. People in England will become the first in the world to receive belantamab mafodotin for this indication, following the recommendation of NICE and the approval of the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) earlier this year. It can halt the blood cancer myeloma for nearly three times longer than current therapies.

Source: National Institute for Health and Care Excellence - June 13, 2025